PTEN is widely recognized as a major tumor suppressor, and its somatic alterations, such as point mutations, deletions, or epigenetic silencing via hypermethylation, can lead to the loss or inactivation of one allele, a characteristic observed in several advanced cancers, including PCa. The gene discussed is PTEN; the disease is posterior cortical atrophy.